OGA and hepatocellular carcinoma: Our data also showed that OGT instead of OGA levels varied a lot between Hep3B and PLC/PRF/5 cells, and both OGT knockdown and OGT enzymatic-activity inhibition with ST07892528 or ST04584928 decreased the O-GlcNAcylation on Rab3A in Hep3B cells, indicating that aberrant O-GlcNAcylation of Rab3A in HCC cells mainly results from the changes of OGT levels (Fig. 3a–c and Additional file 4: Figure S3b–c).